[Therapy of Parkinsonian syndrome using L-dopa. Current state and problems].
D000284:Administration, Oral; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D003863:Depression / Q000209:etiology; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D005860:Germany, West; D006801:Humans; D007360:Intelligence; D010302:Parkinson Disease, Secondary / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D011605:Psychoses, Substance-Induced / Q000209:etiology; D012701:Serotonin / Q000378:metabolism; D012893:Sleep Wake Disorders / Q000188:drug therapy / Q000209:etiology; D014641:Vanillic Acid / Q000134:cerebrospinal fluid
D012701:Serotonin; D004295:Dihydroxyphenylalanine; D002262:Carboxy-Lyases; D014641:Vanillic Acid
Die L-Dopa-Therapie des Parkinson-Syndroms. Stand und Probleme